---
title: "Smruthi Organics Ltd (540686) — Share Price, Financials & Analysis"
symbol: "540686"
company: "Smruthi Organics Ltd"
canonical: "https://tapetide.com/stocks/540686"
isin: "INE172E01011"
nse_symbol: "SMRUTHIORGANICSLTD"
bse_code: "540686"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 185.47
generated_at: "2026-09-13T19:15:27.742Z"
---

# Smruthi Organics Ltd (540686)

Canonical page: https://tapetide.com/stocks/540686

## Company

- **NSE Symbol:** SMRUTHIORGANICSLTD
- **BSE Code:** 540686
- **ISIN:** INE172E01011
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2017-08-29
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** smruthiorganics.com

## About

Incorporated in 1989, Smruthi Organics Ltd
 is a manufacturer of Active Pharmaceutical Ingredients[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:43:15.403250Z.

- **Market Cap:** ₹185.47 Cr
- **Classification:** Microcap
- **P/E (reported):** 25
- **EPS (TTM):** ₹6.47
- **EPS (reported):** ₹0.33
- **Book Value:** ₹64.22
- **Price to Book:** 2.51
- **Dividend Yield:** 0.93%
- **ROE:** 4.66%
- **ROCE:** 8.25%
- **Debt to Equity:** 0.11
- **Revenue (yearly):** ₹102.1 Cr
- **Net Income:** ₹3.4 Cr
- **EBITDA:** ₹13.2 Cr
- **52-Week High:** ₹175.3
- **52-Week Low:** ₹95
- **RSI (14):** 68.33

## Tapetide Score

- **Score:** 61 / 100
- **Score date:** 2026-09-04
- **Archetype:** Quality at a Reasonable Price
- **What it means:** Financial strength is not being paid for with a demanding multiple. The question worth asking is whether the quality is durable or reflects a good patch — check the consistency of returns over several years rather than the latest quarter.
- **Pillar profile:** Quality: Good · Valuation: Cheap · Momentum: Rising
- **Percentile:** 90.4 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 68.4 | 9% |
| growth | 30.3 | 9% |
| momentum | 87.93 | 12% |
| ownership | 50 | 24% |
| quality | 72.76 | 22% |
| valuation | 61.09 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company has been maintaining a healthy dividend payout of 48.7%
- Debtor days have improved from 93.5 to 69.1 days.

### Weaknesses

- The company has delivered a poor sales growth of -4.22% over past five years.
- Company has a low return on equity of 5.14% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 123.05% | 405.91% | 925.81% |
| ebitda margin growth | 52.63% | 32.48% | 36.84% | -9.16% |
| net income growth | 163.64% | -5.56% | -3% | -26% |
| revenue growth | 0.69% | -19.03% | -10% | -4% |
| roce | — | -1.67% | -1.55% | 10.62% |
| roe | — | -6.24% | 4.93% | -69.86% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 29.59 | 23.48 | 39.66 | 27.27 | 29.39 | 31.25 | 38.09 | 18.85 | 31.6 | 22.29 | 29.05 | 29.3 |
| Expenses | 25.16 | 24.66 | 35.58 | 26.82 | 26.5 | 27.08 | 33.41 | 18.56 | 26.59 | 18.29 | 25.15 | 23.49 |
| Operating Profit | 4.43 | -1.18 | 4.08 | 0.45 | 2.89 | 4.17 | 4.68 | 0.29 | 5.01 | 4 | 3.9 | 5.81 |
| OPM % | 14.97 | -5.03 | 10.29 | 1.65 | 9.83 | 13.34 | 12.29 | 1.54 | 15.85 | 17.95 | 13.43 | 19.83 |
| Other Income | 0 | 0 | 0.06 | 0 | 0.01 | 0 | 0.08 | 0.04 | 0.01 | -0.44 | -0.07 | -0.04 |
| Interest | 0.39 | 0.32 | 0.37 | 0.41 | 0.44 | 0.51 | 0.52 | 0.46 | 0.66 | 0.25 | 0.31 | 0.31 |
| Depreciation | 1.38 | 1.45 | 1.59 | 1.29 | 1.33 | 1.37 | 1.5 | 1.41 | 1.51 | 1.67 | 1.75 | 1.6 |
| Profit before tax | 2.66 | -2.95 | 2.18 | -1.25 | 1.13 | 2.29 | 2.74 | -1.54 | 2.85 | 1.64 | 1.77 | 3.86 |
| Tax % | 22.56 | -22.03 | 30.73 | -26.4 | 31.86 | 35.37 | 18.61 | -28.57 | 27.72 | 14.63 | 39.55 | 25.65 |
| Net Profit | 2.07 | -2.29 | 1.52 | -0.92 | 0.78 | 1.48 | 2.23 | -1.1 | 2.06 | 1.4 | 1.07 | 2.88 |
| EPS in Rs | 1.81 | -2 | 1.33 | -0.8 | 0.68 | 1.29 | 1.95 | -0.96 | 1.8 | 1.22 | 0.93 | 2.52 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 97 | 137 | 131 | 126 | 133 | 141 | 128 | 126 | 102 | 112 |
| Expenses | 94 | 121 | 116 | 98 | 115 | 131 | 116 | 114 | 89 | 94 |
| Operating Profit | 3 | 17 | 15 | 29 | 18 | 10 | 12 | 12 | 13 | 19 |
| OPM % | 3.4 | 12 | 12 | 23 | 14 | 7 | 9 | 10 | 13 | 17 |
| Other Income | 0 | 1 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | -1 |
| Interest | 4 | 4 | 3 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 6 | 6 | 6 | 7 |
| Profit before tax | -5 | 10 | 12 | 24 | 14 | 4 | 5 | 5 | 5 | 10 |
| Tax % | -31 | 30 | 30 | 29 | 25 | 8 | 28 | 27 | 27 | — |
| Net Profit | -3 | 7 | 8 | 17 | 10 | 4 | 4 | 4 | 3 | 7 |
| EPS in Rs | -2.82 | 6.02 | 7.41 | 14.95 | 9.07 | 3.61 | 3.14 | 3.11 | 3 | 6.47 |
| Dividend Payout % | 0 | 11 | 14 | 20 | 33 | 55 | 48 | 48 | 50 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 4 | 4 | 4 | 4 | 11 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 28 | 25 | 33 | 39 | 49 | 56 | 57 | 58 | 60 | 62 |
| Borrowings | 33 | 31 | 28 | 16 | 10 | 3 | 6 | 12 | 17 | 8 |
| Other Liabilities | 20 | 25 | 37 | 30 | 21 | 18 | 32 | 37 | 23 | 22 |
| Total Liabilities | 85 | 85 | 101 | 88 | 92 | 88 | 106 | 118 | 112 | 104 |
| Fixed Assets | 30 | 30 | 30 | 32 | 31 | 33 | 37 | 40 | 45 | 47 |
| CWIP | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 1 | 3 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 54 | 54 | 69 | 56 | 60 | 53 | 66 | 77 | 64 | 54 |
| Total Assets | 85 | 85 | 101 | 88 | 92 | 88 | 106 | 118 | 112 | 104 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 9 | 5 | 12 | 21 | 23 | 2 | 12 | 4 | 10 | 22 |
| Cash from Investing Activity | 0 | -3 | -4 | -5 | -3 | 7 | -10 | -7 | -11 | -9 |
| Cash from Financing Activity | -9 | -2 | -5 | -17 | -7 | -12 | -2 | 3 | 1 | -12 |
| Net Cash Flow | 0 | 0 | 2 | -1 | 13 | -3 | 0 | 0 | 0 | 1 |
| Free Cash Flow | 8 | 1 | 7 | 17 | 19 | -4 | 3 | -4 | -2 | 14 |
| CFO/OP | 93 | 159 | 71 | 160 | 101 | 33 | 136 | 46 | 100 | 182 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 97 | 95 | 97 | 68 | 62 | 78 | 96 | 117 | 94 | 69 |
| Inventory Days | 145 | 126 | 92 | 75 | 100 | 91 | 96 | 150 | 151 | 228 |
| Days Payable | 123 | 130 | 120 | 97 | 81 | 50 | 98 | 144 | 85 | 111 |
| Cash Conversion Cycle | 119 | 92 | 68 | 46 | 80 | 118 | 93 | 123 | 160 | 186 |
| Working Capital Days | 1 | 7 | 78 | 32 | 52 | 99 | 73 | 94 | 92 | 85 |
| ROCE % | 10 | -1 | 21 | 25 | 39 | 21 | 7 | 8 | 8 | 8 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 63.58% | 63.6% | 63.84% | 63.87% | 63.87% | 63.87% | 64.73% | 64.73% | 64.73% | 64.73% | 64.73% | 64.73% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 29.9% | 29.84% | 29.56% | 29.52% | 29.57% | 29.54% | 28.83% | 28.81% | 28.86% | 28.83% | 28.71% | 28.65% |
| Others | 6.52% | 6.56% | 6.6% | 6.61% | 6.56% | 6.59% | 6.44% | 6.47% | 6.41% | 6.44% | 6.57% | 6.62% |
| No. of Shareholders | 5605 | 5752 | 5877 | 5869 | 5972 | 5959 | 5905 | 6047 | 6356 | 6187 | 6035 | 5959 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 6 / 0

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 154.42 | Buy |
| EMA (10) | 154.93 | Buy |
| SMA (20) | 141.51 | Buy |
| EMA (20) | 145.72 | Buy |
| SMA (50) | 127.84 | Buy |
| EMA (50) | 133.07 | Buy |
| SMA (100) | 122.61 | Buy |
| EMA (100) | 126.23 | Buy |
| SMA (200) | 119.71 | Buy |
| EMA (200) | 122.79 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 66.74 | Neutral |
| MACD (12,26,9) | 10.88 | Buy |
| Stochastic (14,3,3) | 79.74 | Neutral |
| ADX (14) | 61.28 | Buy |
| Williams %R (14) | -31.54 | Neutral |
| ATR (14) | 8.9 | High Volatility |
| ROC (12) | 21.38 | Buy |
| Stoch RSI (14) | 22.75 | Neutral |
| UO (7,14,28) | 56.27 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c01e9a5b-a825-49bb-947d-e10ee30f19e8.pdf) |
| 2026-08-10 | [Board Meeting Outcome for Un Audited Quarterly Results Of The Company For The First Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3579ac04-f907-4f1e-a6b5-16317ead57ee.pdf) |
| 2026-08-10 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=53df3880-5d84-4ae1-89f7-5a82ca14ccf7.pdf) |
| 2026-08-10 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=751a17d3-4274-46fe-8c53-5776a6162cc9.pdf) |
| 2026-07-30 | [Board Meeting Intimation for Unaudited Financial Results Of The Company For The First Quarter Ended 30Th June 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=edc26172-81af-4264-bf87-74cabf2812e2.pdf) |
| 2026-07-21 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=18400281-7ffa-4aaf-b904-9c2eb0863ab6.pdf) |
| 2026-07-17 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b6235912-ac25-46f4-bcd3-27658fd2cc88.pdf) |
| 2026-07-17 | [Notice Of Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3588b6ba-6d06-467a-9e2b-667d980cbc29.pdf) |
| 2026-07-16 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=461d39ff-2f33-4406-ace0-56eb288128f5.pdf) |
| 2026-07-13 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a59dca6a-2f0d-4d6d-a41d-0a4d39cb9d9f.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-10 | [Un Audited Financial Results Of The Company For The Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fd444d55-b3b2-4247-9f6e-2347922652ec.pdf) |
| 2026-05-13 | [Audited Financial Results For The Quarter And Financial Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3264e39f-8d92-4465-b63f-038a79f3d69a.pdf) |
| 2026-02-13 | [Financial Results For The Quarter Ended 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50e16328-5cf0-44b1-aadf-2b810122bfe1.pdf) |
| 2025-11-11 | [Financial Results For Quarter And Half Year Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2f8b5962-0cc5-4e01-ba11-ce39942c848b.pdf) |
| 2025-08-13 | [Financial Results For The Quarter Ended 30Th June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=830d6e6a-61a1-428d-823b-bff7387a9d0e.pdf) |
| 2025-05-05 | [Financial Results For The Fourth Quarter And Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f7d2664-29a1-486b-84a9-bb7a310465c2.pdf) |
| 2025-05-05 | [Financial Results For The Fourth Quarter And Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=017c8e08-1f2f-4c69-97b1-f91d34f10f2d.pdf) |
| 2025-02-04 | [Financial Results For Quarter Ended 31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9178b82e-6d52-4d0a-9a9a-4783019c4c91.pdf) |
| 2024-11-14 | [Unaudited Financial Results For The Second Quarter And Half Year Ended 30Th September, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d0ec723b-0f31-42c9-a900-3b601da2dffa.pdf) |
| 2024-07-27 | [Unaudited Financial Results For The First Quarter Ended 30Th June 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62f1c61f-7d77-4618-8c23-543f1cb19dad.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Mar - Received EDQM CEP for Amlodipine Besilate on 09 Mar 2026 enabling EU market supply. | [Intimation Under Regulation 30 Of SEBI (LODR) Regulations - Receipt Of CEP Certificate From EDQM 9 Mar - Received EDQM CEP for Amlodipine Besilate on 09 Mar 2026 enabling EU market supply.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ec8bb157-acc6-4ee3-aa45-ee24e7ab0914.pdf) |
| 7 Feb - Board meeting on Feb 13, 2026 to consider unaudited standalone and consolidated results for quarter ended Dec 31, 2025. | [Board Meeting Intimation for Approval And Take On Record The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended December 31, 2025. 7 Feb - Board meeting on Feb 13, 2026 to consider unaudited standalone and consolidated results for quarter ended Dec 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8d9b8119-b73f-4fd8-a3a9-cde33826b4da.pdf) |
| 7 Apr - Quarter ended 31 March 2026 Regulation 74(5) dematerialisation confirmation issued. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Quarter ended 31 March 2026 Regulation 74(5) dematerialisation confirmation issued.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2e70012a-b674-43ba-b4e5-44e04a5c1984.pdf) |
| 6 May - Board meets 13 May 2026 to approve audited FY26 results and consider dividend. | [Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (LODR) Regulations, 2015 6 May - Board meets 13 May 2026 to approve audited FY26 results and consider dividend.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/880e20d3-beb4-4a2d-8ab7-e46d05b0e81f.pdf) |
| 4 Mar - EDQM attestation confirms EU GMP compliance for Amlodipine Besilate after 27–29 Aug 2025 inspection at Solapur Unit II. | [Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Receipt Of "Attestation Of Inspection" From EDQM 4 Mar - EDQM attestation confirms EU GMP compliance for Amlodipine Besilate after 27–29 Aug 2025 inspection at Solapur Unit II.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/eb46b7cd-35a2-4b73-b81a-c4784085f912.pdf) |
| 16 Feb - Unaudited standalone and consolidated results for quarter ended Dec 31, 2025 published Feb 14, 2026. | [Unaudited Financial Results For The Quarter Ended December 31, 2025 Published In The Newspapers 16 Feb - Unaudited standalone and consolidated results for quarter ended Dec 31, 2025 published Feb 14, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9f4bea12-775a-461f-a3e7-6ea415f66827.pdf) |
| 13 Feb - Unaudited Q3/9-month results to 31 Dec 2025; net profit Rs139.79L (quarter), Rs235.87L (9M); exceptional Rs45.17L gratuity. | [Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, 13Th February 2026 13 Feb - Unaudited Q3/9-month results to 31 Dec 2025; net profit Rs139.79L (quarter), Rs235.87L (9M); exceptional Rs45.17L gratuity.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bcec56b0-88c4-416c-925e-a6dec2cddabf.pdf) |
| 13 Feb - Re-appointment of Mr. Sunil Jha as MD from March 4, 2026 to March 3, 2029. | [Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 ('Listing Regulations') 13 Feb - Re-appointment of Mr. Sunil Jha as MD from March 4, 2026 to March 3, 2029.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2036a2eb-126b-4ae4-bbef-b9e56af0d86a.pdf) |
| 13 Feb - Board approved Q3/9M FY26 results; auditor qualified; Rs.11,828.33 lakh unpaid interest; Rs.76,100 lakh arbitration award; going-concern doubts. | [Board Meeting Outcome for Outcome Of The Board Meeting Held On February 13, 2026 13 Feb - Board approved Q3/9M FY26 results; auditor qualified; Rs.11,828.33 lakh unpaid interest; Rs.76,100 lakh arbitration award; going-concern doubts.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/99b88b6d-c297-4a20-813b-e01dd7e2f859.pdf) |
| 13 Feb - Board approved Q3/9M Dec 31, 2025 results; auditor qualified; unpaid interest Rs.1,938 lakh; arbitration Rs.76,100 lakh; going-concern doubt. | [Outcome Of The Board Meeting Held On February 13, 2026 13 Feb - Board approved Q3/9M Dec 31, 2025 results; auditor qualified; unpaid interest Rs.1,938 lakh; arbitration Rs.76,100 lakh; going-concern doubt.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/933c5144-d8a4-4c09-ba57-bb095e200727.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6235912-ac25-46f4-bcd3-27658fd2cc88.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8448692c-6223-4363-a125-10a0e79e7019.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9d8a6a04-5170-4b8f-b172-c9d850b7da41.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0537465e-218c-4296-aa9d-7be3f657da29.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7b53b8b8-19ed-4a31-87d6-2d2ce99bfa7f.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bbec543b-7552-4cde-987c-d2e6870ee32c.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/148653d3-d8fe-4608-9225-35947478a10c.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/540686/73683540686.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/511411/75190511411.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/540686/68626540686.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:15:27.742Z.